Intensive glycemic control linked to highest weight gains

March 21, 2013
Intensive glycemic control linked to highest weight gains
Weight gain is higher in patients with type 2 diabetes mellitus who receive more intensive glycemic control treatment and is associated with a reduction of A1C from baseline, according to research published online Feb. 14 in Diabetes Care.

(HealthDay)—Weight gain is higher in patients with type 2 diabetes mellitus (T2DM) who receive more intensive glycemic control treatment and is associated with a reduction of A1C from baseline, according to research published online Feb. 14 in Diabetes Care.

Vivian Fonseca, M.D., of Tulane University's Health Sciences Center in New Orleans, and colleagues studied the determinants of weight gain in 8,929 patients with T2DM from the Action to Control Cardiovascular Risk in Diabetes trial who either participated in standard (4,504) or intensive glycemic control treatment arms (4,425).

The researchers found that patients in the intensive glycemia arm gained an average of 2.7 kg more than those in the standard arm (3.0 versus 0.3 kg). Independent factors associated with weight gain over the two-year treatment duration included younger age, male sex, Asian race, no smoking history, high A1C, baseline of 25 to 35 kg/m², high , baseline insulin use, and baseline metformin use. Overall, medication use was associated with less than 15 percent of the variability in weight change.

"Following randomization, the intensive group participants with the greatest reduction in A1C gained the most weight," the authors write. "Insulin and TZD [thiazolidinedione] use was associated with the greatest weight gain. Nevertheless, appreciation of these characteristics may help develop strategies to prevent weight gain when initiating intensive glycemic control in the future."

Explore further: Dapagliflozin aids glycemic control in type 2 diabetes

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Dapagliflozin aids glycemic control in type 2 diabetes

March 20, 2012

(HealthDay) -- For patients with inadequately controlled type 2 diabetes, treatment with dapagliflozin is associated with improved glycemic control, stabilized insulin dosing, and weight reductions, according to research ...

Pre-op factors predict post-gastric op glycemic response

October 8, 2012

(HealthDay)—The glycemic response to gastric bypass surgery can be predicted in Chinese patients with type 2 diabetes by three preoperative factors, according to a study published online Oct. 1 in Diabetes Care.

T1DM insulin intensification patterns, outcomes studied

January 30, 2013

(HealthDay)—About half of youths with type 1 diabetes shift to a more intensive insulin regimen over time, which is associated with better glycemic control, according to research published in the January issue of Diabetes ...

Recommended for you

Engineered hot fat implants reduce weight gain in mice

August 20, 2015

Scientists at the University of California, Berkeley, have developed a novel way to engineer the growth and expansion of energy-burning "good" fat, and then found that this fat helped reduce weight gain and lower blood glucose ...

Bacteria may cause type 2 diabetes

June 1, 2015

Bacteria and viruses have an obvious role in causing infectious diseases, but microbes have also been identified as the surprising cause of other illnesses, including cervical cancer (Human papilloma virus) and stomach ulcers ...

Promising progress for new treatment of type 1 diabetes

July 30, 2015

New research from Uppsala University shows promising progress in the use of anti-inflammatory cytokine for treatment of type 1 diabetes. The study, published in the open access journal Scientific Reports, reveals that administration ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.